Global Cervical Cancer Diagnostic Tests Market: Prevalence of Cervical Cancer in Low-income Nations to Accelerate Growth

Cervical cancer is the third most common cancer among women and has become the second most common cause of cancer-related deaths across the globe. The deadly disease accounts for around 300,000 deaths annually. Appropriate screening methods and diagnostic tests help in early detection of cervical cancer. The global cervical cancer diagnostic tests market is estimated to expand at a CAGR of 6.10% during the period between 2014 and 2020. The overall market was worth US$5.9 bn in 2013 and is expected to reach a valuation of US$8.9 bn by 2020. 

Browse Full Report: http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html

Diagnostic Tests in High-Income Nations Curbing Occurrence of Cervical Cancer

One of the most common risk factors for cervical cancer is infection by the human papilloma virus (HPV). Other risk factors include smoking, Chlamydia infection, long-term use of oral contraceptives, family history of cervical cancer, and others. HPV testing, Pap smear tests, endocervical curettage (ECC), cone biopsy, loop electrosurgical excision procedure (LEEP), and colposcopy are some of the commonly used diagnostic tests for cervical cancer. In 2013, Pap smear tests accounted for more than 45% of the global cervical cancer diagnostic tests market owing to the high efficacy of the tests at relatively low costs. However, the low cost of Pap smear tests has not helped to decrease the number of patients affected with cervical cancer across lower income countries. 

According to a new study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research, the prevalence of infection-related cancers such as stomach, liver, and cervical cancers as well as lung, breast, and colorectal cancers has increased in low- and middle-income countries. The increasing prevalence of cervical cancer is a major concern across Southeast Asia, Sub-Saharan Africa, Central and Eastern Europe, and Latin America and the Caribbean. In high-income nations, screening programs implemented years ago have helped to curb cervical cancer rates by as much as 4% annually. 

Cervical Cancer Prevention Program in Haiti: A Concrete Step to Fight the Disease

In Haiti, around 3,000 women get cervical cancer each year and almost half of them die from the illness. In fact, the country registers the highest rate of cervical cancer across the world. Partners in Health, a Boston-based non-profit organization, has launched a two-year pilot program in Haiti to screen 20,000 women for cervical cancer and vaccinate around 6,000 girls against the strains of human papilloma virus. Zanmi Lasante, the Haitian program of Partners in Health, plans to reach around to 60,000 people, making them aware about the disease.  

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/cervical-cancer-diagnostic-tests-market.htm

In the near future, the global cervical cancer diagnostic tests market is expected to gain impetus from the demand arising from low- and middle-income countries. Though these countries lack resources to fight against the disease, development of cervical cancer prevention strategy along with donation of vaccines and other supplies will help to decrease the prevalence of the disease. For example, in Haiti, the U.S. Agency for International Development is supporting the pilot program launched by Zanmi Lasante. To avail vaccines and other supplies for the patients, the non-profit organization is coordinating with drug manufacturing company Merck & Co. 

Global Cervical Cancer Diagnostic Tests Market to reach US$8.9 bn by 2020, Propelled by Increased Cervical Cancer Patients

Cancer Care Manitoba demonstrated cancer testing procedures at Winnipeg’s Health Science Centre (HSC) recently, as part of the cervical cancer awareness week. The main focus of this program was to exhibit liquid-based cytology testing. Liquid-based cytology testing is a process that reduces the need for retesting. Samples of cervical cancer are collected through a process called pap test. This method of collecting samples of cervical cancer allows accurate and quick analysis.

Browse Full Report: http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html

In Manitoba, every year, nearly 45 women are identified with cervical cancer and the number is growing rapidly. 80% of cervical cancer cases can be basically prevented by regular screening. Sharon Blady, the minister of health, was present at the Health Science Centre, where various testing methods for cervical cancer were addressed and demonstrated. According to the CervixCheck program, every sexually active women should receive a pap test once every three years, right from the age of 21.

Pap Smear Test Sector to Expand at 6.0% CAGR till 2020

The global cervical cancer diagnostic tests market was valued at US$5.9 bn in 2013 and is expected to reach US$8.9 bn by 2020. The increasing number of cancer patients is expected to propel the global cervical cancer diagnostic tests market at a 6.10% CAGR during the period from 2013 to 2020.

The global cervical cancer diagnostic tests market is segmented on the basis of the type of tests performed and geography. By the type of test, the global cervical cancer diagnostic tests market is classified into HPV testing, pap smear tests, colposcopy, and endocervical curettage procedure. In 2013, the HPV testing sector dominated the global cervical cancer diagnostic tests market. The increasing incidence of HPV infection and increasing number of people who smoke is expected to drive the HPV testing sector during the forecast period. The pap smear test sector is predicted to expand at a 6.0% CAGR till 2020 due to the possibility of early detection of cell abnormalities through this test. Demand for other types of tests such as LEEP and ECC is also expected to increase steadily.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/cervical-cancer-diagnostic-tests-market.htm 

North America to Account for Highest Global Market Share

By geography, the global cervical cancer diagnostic tests market is classified into North America, Asia Pacific, Europe, and Rest of the World. In 2013, the global cervical cancer diagnostic tests market was led by the North America regional cervical cancer diagnostic tests market. The Asia Pacific regional segment is predicted to register the highest market share by the end of the forecast period due to factors such as easy market penetration, low labor costs, and tax benefits. Some of the prominent players in the global cervical cancer diagnostic tests market are Becton, Hologic, Inc., Guided Therapeutics, Abbott Laboratories, Dickinson and Company, Guided Therapeutics, OncoHealth Corp., Roche Diagnostics, Zilico Ltd., Quest Diagnostics, Inc., and QIAGEN.

Cervical Cancer Diagnostic Tests Market to Rise Thanks to Benefits Associated with HPV and Pap Co-testing

The cervical cancer diagnostic tests market is expanding at a swift pace owing to the rising number of deaths caused by cervical cancer all around the globe. As per the World Health Organization, cervical cancer is responsible for causing over 270,000 deaths each year, especially in emerging countries. The swift spread of the human papillomavirus in females, the consistent usage of oral contraceptive pills, and weakening immune systems are amongst the key factors driving demand from the cervical cancer diagnostic tests market. This is why diagnostic tests such as Pap smear tests, colposcopy, and HPT testing are used for the early detection of cervical cancer in individuals. 

TMR, a market intelligence company, has studied the functioning and credibility of these tests and has thrown light on the various limitations of these tests. As per TMR, the global cervical cancer diagnostic tests market stood at US$5.9 billion in 2013 and is predicted to expand at a CAGR of 6.1% between 2014 and 2020 to reach US$8.9 billion by 2020.

Browse Market Research Report of Cervical Cancer Diagnostic Tests Market: http://www.transparencymarketresearch.com/cervical-cancer-diagnostic-tests-market.html

Is HPV Testing Alone Beneficial for Cervical Cancer Screening? 

The Food and Drug Administration, in April 2014, approved the utilization of HPV DNA test as the first-line primary screening test to be utilized on women aged 25 and above. The test helps in the diagnosis of HPV types 18 and 16 and provides pooled results for 12 more high-risk HPV types. This new approval was given after performing clinical trials including over 47,000 women. The trial results demonstrated that the HPV test utilized in the study had a better performance as compared to the Pap smear test in identifying women who are at risk of developing acute cervical cell abnormalities. 

What are the Major Benefits of HPV and Pap Co-Testing?

HPV and Pap co-testing is highly advantageous for women aged 30 or older, as this co-testing has a much lower chance of missing an abnormality as compared to Pap testing done alone. Hence, women having a normal Pap and negative HPV test in conjunction have a minimal chance of developing an undetected serious abnormality in the coming years. HPV and Pap co-testing may also enhance the detection of glandular cell abnormalities, such as cancer of glandular cells of the cervix. 

Browse Market Research Press Release of Cervical Cancer Diagnostic Tests Market: http://www.transparencymarketresearch.com/pressrelease/cervical-cancer-diagnostic-tests-market.htm

Are There any Limitations Associated with Cervical Cancer Diagnostic Tests?

Though cervical cancer diagnostic tests are very effective, they are not yet fully accurate.  There are many limitations on cervical cancer screening owing to the nature of HPV infections. HPV infections are transient in nature and create momentary changes in the cervical cells. This is why regular cervical screening may detect cervical cell changes and HPV infections that may never initiate cancer. Additionally, these tests may present normal cells as abnormal, or vice versa, due to the transience of the condition. These limitations may restrain the usage of cervical cancer diagnostic tests in the forthcoming years.

Becton, Abbott Laboratories, Dickinson and Company, Guided Therapeutics, Hologic, Inc., OncoHealth Corp., Femasys, Inc., Quest Diagnostics, Inc., QIAGEN, Roche Diagnostics, and Zilico Ltd. are amongst the prime players dominant in the market for cervical cancer diagnostic tests.